Module Database Search
| MODULE DESCRIPTOR | |||
|---|---|---|---|
| Module Title | |||
| Advances in Pharmaceutical Science and Practice | |||
| Reference | PLM004 | Version | 1 |
| Created | April 2022 | SCQF Level | SCQF 11 |
| Approved | June 2022 | SCQF Points | 30 |
| Amended | August 2021 | ECTS Points | 15 |
| Aims of Module | |||
|---|---|---|---|
| To provide the student with the ability to appraise developing areas in the pharmaceutical sciences and clinical practice. | |||
| Learning Outcomes for Module | |
|---|---|
| On completion of this module, students are expected to be able to: | |
| 1 | Discuss the principles underlying selected current developments in the pharmaceutical sciences and pharmacy practice. |
| 2 | Critically appraise novel stratified medicine to explore its advantages and disadvantages in clinical practice. |
| 3 | Critically evaluate aspects of pharmacology pertinent to the development of personalised medicines. |
| 4 | Evaluate literature in the pharmaceutical sciences and clinical practice, including presentation, analysis and appraisal of selected publications. |
| Indicative Module Content |
|---|
| This module will reflect forefront topics in both pharmaceutical sciences and clinical practice. Suggested topics may include: Pharmacogenomics; disease susceptibility; cell and gene therapy; immunotherapy; science of the practice of delivering biopharmaceuticals; personalised medicines; age related medicines; digital health. |
| Module Delivery |
|---|
| Lectures, coursework sessions (that include individual problem solving exercises and group based problem-based learning, tutorial sessions) and directed study (that include computer packages, directed reading and selfâassessment exercises). |
| Indicative Student Workload | Full Time | Part Time |
|---|---|---|
| Contact Hours | 60 | N/A |
| Non-Contact Hours | 240 | N/A |
| Placement/Work-Based Learning Experience [Notional] Hours | N/A | N/A |
| TOTAL | 300 | N/A |
| Actual Placement hours for professional, statutory or regulatory body |
| ASSESSMENT PLAN | |||||
|---|---|---|---|---|---|
| If a major/minor model is used and box is ticked, % weightings below are indicative only. | |||||
| Component 1 | |||||
| Type: | Coursework | Weighting: | 100% | Outcomes Assessed: | 1, 2, 3, 4 |
| Description: | A written assignment | ||||
| MODULE PERFORMANCE DESCRIPTOR | |
|---|---|
| Explanatory Text | |
| A minimum of grade D or better is required to pass this module. | |
| Module Grade | Minimum Requirements to achieve Module Grade: |
| A | When the grade for Component 1(CW1) is an A. |
| B | When the grade for Component 1(CW1) is a B. |
| C | When the grade for Component 1(CW1) is a C. |
| D | When the grade for Component 1(CW1) is a D. |
| E | When the grade for Component 1(CW1) is an E. |
| F | When the grade for Component 1(CW1) is an F. |
| NS | Non-submission of work by published deadline or non-attendance for examination |
| Module Requirements | |
|---|---|
| Prerequisites for Module | Successful completion of MPharm Stage 3 or equivalent. |
| Corequisites for module | None. |
| Precluded Modules | None. |
| INDICATIVE BIBLIOGRAPHY | |
|---|---|
| 1 | FLORENCE, A.T. and ATTWOOD, D., 2016. Physicochemical Principles of Pharmacy. Sixth Edition. London: Pharmaceutical Press. |
| 2 | HO, R.J.Y., GIBALDI, M., 2013. Biotechnology and biopharmaceuticals: transforming proteins and genes into drugs. Second edition. Hoboken, New Jersey : Wiley Blackwell. |
| 3 | TRENT, R.J., 2012. Molecular medicine: genomics to personalised healthcare. Fourth edition. San Diego: Elsevier Science & Technology. |
| 4 | GREENSTEIN, B., BROOK, D.A., 2011. Biological therapeutics. London: Pharmaceutical Press. |